Ali Arash Anoushirvani, Azam Ahmadi, Reza Aghabozorgi, Sara Khalili, Maryam Sahraei, Taha Fereydouni, Zoha Khademi,
Volume 21, Issue 2 (5-2018)
Abstract
Abstract
Background: Breast cancer is the most common cancer in women. It has been proven the association of cause of this disease with changes in several genes. One of the pathways associated with breast cancer is the folate reuptake pathway. The key enzyme of this pathway is coded by the TYMS gene. MicroRNAs control the expression of genes by binding to their regulatory regions. In this study, we evaluated changes in the regulatory region of TYMS gene with demographic characteristics (including the grade of cancer and metastasis) in breast cancer patients.
Materials and Methods: In this study, the regulatory region of TYMS gene was investigated using related bioinformatics software. After collecting cancerous samples and DNA extraction from blood samples of normal and patients, change in the miRNA binding region by digestion with NlaIII enzyme was assayed.
Results: Bioinformatics studies showed that the restriction site of some of the endonuclease enzymes in the 3'-UTR of the TYMS gene is related to the binding region of miRNAs, including Hsa-miR-433-3p. The results indicated the correctness of the genomic purification process, the PCR and enzymatic digestion reaction. In this study, in the regulatory region, CC homozygote, AC heterozygote and AA mutant homozygote variant had differences with control group (OR: 1.3465, %95 CI: 0.7275 to 2.4923, p<0.05). Also, the association of AA genotypes with metastasis and high grade of the patients was confirmed statistically.
Conclusion: Studies have shown that some of polymorphisms in the key genes involved in cancer are directly related to their diagnosis and treatment process, and given the importance of timely diagnosis of cancer, the achievement of diagnostic biomarkers in breast cancer in the early stages will be important. Probably, the nucleotide change at the site of the microRNA binding site could be used as a diagnostic biomarker for degree of tumor progression.
Andia Seyedi Moghaddam, Mahdieh Salimi, Najmeh Ranji, Hossein Mozdarani,
Volume 25, Issue 1 (3-2022)
Abstract
Background and Aim MicroRNAs (miRNAs) are a class of small non-coding RNAs (17-25 nucleotides) that have been studied in many diseases. miRNAs studies in different cancers have shown that miRNAs may be considered oncogene or tumor suppressor. So far, many studies have shown that miR-17-5p and miR-93-5p are important regulatory molecules in some biological processes, such as cell proliferation, associated with cancer formation. This study aimed to investigate and compare the tissue and plasma expression levels of miR-17-5p and miR-93-5p in patients with ductal carcinoma breast cancer with the normal control group.
Methods & Materials The total RNA (including miRNA) was extracted from breast and plasma tissue samples of cancerous and normal samples. The RNA concentration and purity were confirmed using optical absorbance measurements. cDNA was synthesized, and the expression levels of miR-17-5p and miR-93-5p were assessed semi-quantitatively by SYBR Green-based real-time RT-PCR assay in plasma and breast tissues of ductal carcinoma breast cancer compared with the control normal samples with SNORD47 as internal normalizer. Data were statistically evaluated using GraphPad Prism 8.0.2.
Ethical Considerations This study was approved by the Ethics Committee of the institute (IRAN 52d/4922, 6.10.2016). All study individuals signed a consent form to use their clinical samples and personal data under the physician’s supervision.
Results The expression level of miR-17-5p showed significantly higher expression in tissues and plasma of the cancer group compared with the control group (P<0.0001). It was also significantly associated with tumor stage and lymph node, and ER (estrogen receptor) and PR (progesterone receptor) status (P<0.0001). While decreased expression of miR-93-5p in plasma and tumor tissues was shown to be significantly associated with tumor stage and lymph node involvement (P<0.0001).
Conclusion The data revealed that high expression of miR-17-5p and low expression of miR-93-5p in both plasma and breast tumor might be associated with poor prognosis in breast cancer. However, miR-17-5p, due to the greater change in expression and ease of plasma detection, may serve as a possible non-invasive biomarker for breast cancer’s poor prognosis. Further follow-up studies are required to confirm this finding.
Samira Asgharzade, Mana Shojapour,
Volume 26, Issue 4 (11-2023)
Abstract
Background and Aim: Alzheimer's Disease (AD) is a progressive neurodegenerative disease characterized by loss of memory and multiple cognitive impairments.
Materials and Methods: In this study, key terms were searched in reputable Persian and English databases including DOAJ, PubMed, Google Scholar, LISTA (EBSCO), Embase, and Web of Science. Articles focusing on the molecular basis and pathogenesis of the disease, as well as biomarkers for Alzheimer's diagnosis, were reviewed. In this article, we have attempted a comprehensive review not only of the molecular basis of Alzheimer's disease from a molecular medical perspective but also to address numerous molecular diagnostic methods and biomarkers at both clinical and research levels in this disease.
Ethical Considerations: All Ethical principles in writing this article have principles been observed according to the instructions of National Ethics Committee and the COPE regulations
Findings: The results of this review study indicate that the major factors involved in the pathogenesis of Alzheimer's include beta-amyloid peptides, hyperphosphorylation of tau protein, and activation of inflammatory and oxidative stress pathways. Subsequently, this leads to synaptic loss, mitochondrial dysfunction, and proliferation of activated astrocytes and microglia, which are clinically manifested as memory loss in patients."
Conclusion: Although no precise diagnostic method exists for AD, current clinical recommendations for AD diagnosis include assessing tau protein and beta-amyloid (Aβ) peptides in cerebrospinal fluid, magnetic resonance imaging (MRI) for brain volume, and positron emission tomography (PET) scanning for Aβ plaques and/or glucose metabolism in the brain.
